Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from pharmaphorum

00:36 EDT 25th June 2018 | BioPortfolio

Here are the most relevant search results for "pharmaphorum" found in our extensive news archives from over 250 global news sources.

More Information about pharmaphorum on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about pharmaphorum for you to read. Along with our medical data and news we also list pharmaphorum Clinical Trials, which are updated daily. BioPortfolio also has a large database of pharmaphorum Companies for you to search.

Showing News Articles 1–25 of 660 from pharmaphorum

Friday 22nd June 2018

Novo's diabetes pill beats injections in head-to-head trials

Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market. The company announced the completion of two trials of its GLP-1 class drug semaglutide, in ora...

Tesaro stock rockets as rumours of Roche takeover abound

Shares in US biotech Tesaro peaked this week amid speculation that Roche is making plans to buy it. At the time of writing, rumours are rife that the Swiss pharma giant is poised to make public its intention to purchase of Tesaro, which specialise...

Industry urges EU to scrap national HTA bodies

The pharma industry has called for European member states’ national drug value assessment bodies to be abolished if a system to limit drug prices comes into effect across the EU. At the beginning of the year, the European Commission proposed a bin...

Thursday 21st June 2018

Amazon hires surgeon to lead US healthcare revolution

Amazon, Berkshire Hathaway and JP Morgan Chase aim to revolutionise the US healthcare system with a new company – and have hired respected surgeon and writer Atul Gawande to head the operation. The three companies made waves in January when they f...

Opioid misuse lead to at least 456 deaths in UK hospital

Care standards and ethics in the NHS are once again under scrutiny after a report found that overprescription of opiates at Gosport War Memorial Hospital shortened hundreds of lives. Findings of a panel set up by Norman Lamb, a former Minister of ...

Wellcome Trust awards $8m cash injection to trial schizophrenia drug

The Wellcome Trust has awarded $8 million to PureTech’s Karuna to take its schizophrenia drug into mid-stage trials. Karuna, which is an affiliate of PureTech Health, was granted the funding towards the drug KarXT (Karuna-Xanomeline-Trospium), for...

Wellcome Trust awards $8bn cash injection to trial schizophrenia drug

The Wellcome Trust has awarded $8 million to PureTech’s Karuna to take its schizophrenia drug into mid-stage trials. Karuna, which is an affiliate of PureTech Health, was granted the funding towards the drug KarXT (Karuna-Xanomeline-Trospium), for...

Wednesday 20th June 2018

Amgen's blood cancer drug gets full EU licence

Amgen’s Blincyto has been granted a full European licence in a form of blood cancer following data showing the drug almost doubled overall survival time compared with standard therapy. The company said the European Commission granted the marketing...

Roche to buy rest of genetics firm Foundation Medicine

Roche has made an offer to buy the remaining shares in cancer genetics firm Foundation Medicine (FMI) for $2.4 billion. The Swiss pharma giant already bought 56% of FMI in 2015 for $1 billion, and has put in a tender for all of the outstanding FMI...

Sarepta goes up, PTC goes down – DMD research sways the market

US biotech Sarepta's shares jumped by as much as 60% after a gene therapy produced dramatic results in three boys with the muscle wasting disease Duchenne muscular dystrophy (DMD). The company hopes to quickly develop the drug, which works by atte...

Tuesday 19th June 2018

Patients call for end to two-year row over CF drug funding

UK patients are stepping up efforts to resolve the “heartbreaking” row that is denying their families access to Vertex’s groundbreaking cystic fibrosis (CF) drug Orkambi, after Sweden became the latest European country to reimburse it. Vertex has ...

PTC shares soar after SMA drug data impresses market

After failing three times to bring their Duchenne therapy to the US market, PTC Therapeutics might be on verge of a breakthrough in the SMA field. PTC and Roche are co-developing a new spinal muscular atrophy (SMA) drug called risdiplam or RG7916,...

NICE says 'no' to Roche's Perjeta after breast cancer surgery

NICE has rejected Roche’s breast cancer drug Perjeta in patients recovering from surgery on the grounds of expense and efficacy. England’s watchdog has recommended that Perjeta is not used for the treatment of post-surgery patients with early stag...

Monday 18th June 2018

Theresa May's NHS funding pledge insufficient - campaigners

Campaigners have said Prime Minister Theresa May’s pledge to boost NHS coffers by £20 billion a year will be insufficient to meet patients' needs, following years of underfunding. Her promise follows years of financial struggle and the need to mee...

Former Theranos CEO faces criminal fraud charges

Elizabeth Holmes, the founder and former CEO of the blood testing startup Theranos has been criminally charged with fraud, for allegedly making false claims about the effectiveness of the company’s products. Holmes appeared before a US district co...

Eisai accelerates dementia drug discovery research

Eisai is launching a special dementia discovery centre to boost development of next-generation medicines targeting forms of the condition, including Alzheimer’s disease. The new Center for Genetics Guided Dementia Discovery (G2D2) facility is par...

Friday 15th June 2018

Novartis ranked top for corporate reputation in dermatology

Novartis has been ranked the top pharma company in dermatology in a corporate reputation survey of skin condition patient groups. PatientView surveyed patient groups specialising in skin conditions from November 2017 to February 2018 and then anal...

Positive results announced for ViiV Healthcare's two-drug HIV pill

A two-drug strategy has shown positive results, giving new hope to patients with HIV. ViiV Healthcare, which is majority-owned by GlaxoSmithKline, has announced positive results from its phase 3 Gemini study. The studies evaluated the safety and e...

Positive results announced for two-drug HIV pill

A two-drug strategy has shown positive results, giving new hope to patients with HIV. ViiV Healthcare, which is majority-owned by GlaxoSmithKline, has announced positive results from its phase 3 Gemini study. The studies evaluated the safety and e...

J&J's Tremfya gets funding in Germany and UK

Johnson & Johnson’s psoriasis drug Tremfya has been given the green light for funding by cost-effectiveness bodies in the UK and Germany. NICE has published final guidance giving the go-ahead for funding in England after a positive final draft...

Thursday 14th June 2018

J&J seals $2.1bn deal on sale of major diabetes devices firm

As part of its ongoing divestment program, a deal worth $2.1 billion has been struck between Johnson & Johnson (J&J) and US private equity firm Platinum Equity over the sale of the company responsible for the world's leading glucose monitorin...

J&J seals deal on purchase of major diabetes devices firm

A deal worth $2.1 billion has been struck between Johnson & Johnson (J&J) and the firm behind the world-leading glucose monitoring system. Platinum Equity, whose business LifeScan Inc makes the OneTouch devices, made the binding offer to J...

Orphan drugs dominate 2018 UK Prix Galien shortlist

A bumper crop of orphan drugs from the likes of Amicus, Kyowa Kirin, Eusa and Biogen dominates this year’s UK Prix Galien shortlist as biotech firms and specialist pharma companies cement their place as the industry’s innovation engines. Seven rar...

Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete more strongly with older drugs such as AbbVie’s Humira ...

Wednesday 13th June 2018

Information Commissioner urges NHS Trusts to prioritise privacy

The Information Commissioner has ruled that a major hospital failed to comply with the Data Protection Act when it provided patient details to Google’s DeepMind. The Royal Free NHS Trust was deemed not to have fulfilled its legal obligation to mai...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks